Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Предикторы преэклампсии. Скрининг и профилактика в I триместре беременности
Предикторы преэклампсии. Скрининг и профилактика в I триместре беременности
Габидуллина Р.И., Ганеева А.В., Шигабутдинова Т.Н. Предикторы преэклампсии. Скрининг и профилактика в I триместре беременности. Гинекология. 2021; 23 (5): 428–434. DOI: 10.26442/20795696.2021.5.201213
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Изучить современное состояние проблемы прогнозирования и профилактики преэклампсии с ранних сроков беременности.
Материалы и методы. В статье представлен обзор публикаций по результатам поиска в электронных ресурсах PubMed, Elibrary, EMBASE и Google Scholar.
Результаты. Известные на сегодня предикторы преэклампсии можно подразделить на биохимические и гемодинамические. Ряд маркеров демонстрирует прогностическую значимость уже на ранних сроках гестации. Для прогнозирования преэклампсии создаются алгоритмы, включающие различные комбинации ее предикторов и материнских факторов риска.
Заключение. Предикция преэклампсии постепенно переходит из теории в практическую деятельность. Становятся доступными средства раннего ее прогнозирования – до срока гестации 14 (+6) нед, что открывает возможности для проведения адресной и своевременной профилактики.
Ключевые слова: преэклампсия, предикторы, модели прогнозирования
Materials and methods. The article provides an overview of publications based on search results in electronic resources PubMed, Elibrary, EMBASE and Google Scholar.
Results. The currently known predictors of preeclampsia can be divided into biochemical and hemodynamic. A number of markers demonstrate prognostic value already in the early stages of gestation. To predict preeclampsia, algorithms are created. They include various combinations of its predictors and maternal risk factors.
Conclusion. Prediction of preeclampsia is gradually moving from theory to practice. The instruments of its early forecasting – before the gestational age of 14 weeks 6 days – are becoming available. That opens up opportunities for targeted and timely prevention of preeclampsia.
Keywords: preeclampsia, predictors, forecasting models
Материалы и методы. В статье представлен обзор публикаций по результатам поиска в электронных ресурсах PubMed, Elibrary, EMBASE и Google Scholar.
Результаты. Известные на сегодня предикторы преэклампсии можно подразделить на биохимические и гемодинамические. Ряд маркеров демонстрирует прогностическую значимость уже на ранних сроках гестации. Для прогнозирования преэклампсии создаются алгоритмы, включающие различные комбинации ее предикторов и материнских факторов риска.
Заключение. Предикция преэклампсии постепенно переходит из теории в практическую деятельность. Становятся доступными средства раннего ее прогнозирования – до срока гестации 14 (+6) нед, что открывает возможности для проведения адресной и своевременной профилактики.
Ключевые слова: преэклампсия, предикторы, модели прогнозирования
________________________________________________
Materials and methods. The article provides an overview of publications based on search results in electronic resources PubMed, Elibrary, EMBASE and Google Scholar.
Results. The currently known predictors of preeclampsia can be divided into biochemical and hemodynamic. A number of markers demonstrate prognostic value already in the early stages of gestation. To predict preeclampsia, algorithms are created. They include various combinations of its predictors and maternal risk factors.
Conclusion. Prediction of preeclampsia is gradually moving from theory to practice. The instruments of its early forecasting – before the gestational age of 14 weeks 6 days – are becoming available. That opens up opportunities for targeted and timely prevention of preeclampsia.
Keywords: preeclampsia, predictors, forecasting models
Полный текст
Список литературы
1. Ходжаева З.С., Яроцкая Е.Л., Баранов И.И. Инициатива по преэклампсии Международной федерации гинекологии и акушерства (FIGO): практическое руководство по скринингу в I триместре и профилактике заболевания (адаптированная версия на русском языке). Акушерство и гинекология: новости, мнения, обучение. 2019;7(4):32-60 [Khodzhaeva ZS, Yarotskaya EL, Baranov II. Initsiativa po preeklampsii Mezhdunarodnoi federatsii ginekologii i akusherstva (FIGO): prakticheskoe rukovodstvo po skriningu v I trimestre i profilaktike zabolevaniya. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2019;7(4):32-60 (in Russian)]. DOI:10.24411/2303-9698-2019-14003
2. Hypertension in pregnancy: diagnosis and management. NICE guideline. 2019. Available at: www.nice.org.uk/guidance/ng133. Accessed: 20.10.2021.
3. American College of Obstetricians and Gynecologists. Committee opinion No. 638: first-trimester risk assessment for early-onset preeclampsia. Obstet Gynecol. 2015;126:25-7.
4. Адамян Л.В., Артымук Н.В., Башмакова Н.В., и др. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол), утв. МЗ РФ 7 июня 2016 №15-4/10/2-3484. М., 2016 [Adamyan LV, Artymuk NV, Bashmakova NV, et al. Gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode. Preeklampsiya. Eklampsiya. Klinicheskie rekomendatsii (protokol), utv. MZ RF 7 iyunya 2016 №15-4/10/2-3484. Moscow, 2016 (in Russian)].
5. Boutin A, Gasse C, Demers S, et al. Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study. J Obstet Gynaecol Canada. 2017;40(5):572-8. DOI:10.1016/j.jogc.2017.07.025
6. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:237-60.
7. Sandström A, Snowden JM, Höijer J, et al. Clinical risk assessment in early pregnancy for preeclampsia in nulliparous women: A population based cohort study. PLoS ONE. 2019;14(11):1-16.
8. Wainstock T, Sergienko R, Sheiner JE. Who Is at Risk for Preeclampsia? Risk Factors for Developing Initial Preeclampsia in a Subsequent Pregnancy. J Clin Med. 2020;9:1103. DOI:10.3390/jcm9041103
9. Mosimann B, Amylidi-Mohr S, Surbek D, et al. First trimester screening for preeclampsia – a systematic review. Hypertens Pregnancy. 2019;39(1):1-11.
DOI:10.1080/10641955.2019.1682009
10. Amaral LM, Wallace K, Owens M, et al. Pathophysiology and Current Clinical Management of Preeclampsia. Curr Hypertens Rep. 2017;198:61.
11. Duan H, Zhao G, Xu B, et al. Maternal Serum PLGF, PAPPA, β-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia. Clin Lab. 2017;63(5):921-5.
12. Capriglione S, Plotti F, Terranova C, et al. Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. 2018;33(4):677-86. DOI:10.1080/14767058.2018.1495191
13. Goetzinger KR, Zhong Y, Cahill AG, et al. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013;32:1593-600.
14. Ratnik K, Rull K, Hanson E. Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. J Appl Lab Med. 2020;5(6):1156-71.
15. Karumanchi J, Roberts J, Taylor R. First-trimester placental growth factor, SFLT-1, and risk for preeclampsia. AJOG. 2003;189(6):14.
16. Robinson J, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007;197(2):174.e1-e5.
17. Maynard S, Simas T, Bur L. Soluble Endoglin for the Prediction of Preeclampsia in a High Risk Cohort. Hypertens Pregnancy. 2010;29(3):330-41.
18. Stepan H, Herraiz I, Schlembach D. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45(3):241-6.
19. Николаева А.Е., Кайка И.А., Юабова Е.Ю., и др. Преэклампсия. Возможности прогнозирования. Акушерство и гинекология Санкт-Петербурга. 2017;1:8-12 [Nikolaeva AE, Kajka IA, Yuabova EY, et al. Preeklampsiya. Vozmozhnosti prognozirovaniya. Akusherstvo i ginekologiya Sankt-Peterburga. 2017;1:8-12 (in Russian)].
20. Luewan S, Teja M, Sirichotiyakul S, et al. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-9. DOI:10.11622/smedj.2017034
21. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 2008;115:1465-72.
22. Akolekar R, Syngelaki A, Beta J, et al. Maternal serum placental protein 13 at 11–13 weeks of gestation in pre-eclampsia. Prenat Diagn. 2009;29:1103-8.
23. Soongsatitanon A, Phupong V. Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med. 2020;16:1-6. DOI:10.1080/14767058.2020.1849127
24. Taylor BD, Ness RB, Olsen J, et al. Serum Leptin Measured in Early Pregnancy Is Higher in Women With Preeclampsia Compared With Normotensive Pregnant Women. Hypertension. 2015;65:594-9.
25. Akolekar R, Etchegaray A, Zhou Y, et al. Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25:320-7.
26. Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:753-60.
27. Низяева Н.В., Кан Н.Е., Тютюнник В.Л., и др. МикроРНК как важные диагностичеcкие предвестники развития акушерской патологии. Вестник РАМН. 2015;70(4):484-92 [Nizyaeva NV, Kan NE, Tyutyunnik VL, et al. MikroRNK kak vazhnye diagnosticheckie predvestniki razvitiya akusherskoi patologii. Vestnik RAMN. 2015;70(4):484-92 (in Russian)]. DOI:10.15690/vramn.v70.i4.1416
28. Yin Y, Liu M, Yu H, et al. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;253:121-32.
29. Tarca AL, Romero R, Erez O, et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. J Matern Fetal Neonatal Med. 2020;33:1-12. DOI:10.1080/14767058.2019.1685964
30. Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci. 2019;20(12):2972. DOI:10.3390/ijms20122972
31. Bellos I, Pergialiotis V, Papapanagiotou A. Association between serum copeptin levels and preeclampsia risk: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;250:66-73. DOI:10.1016/j.ejogrb.2020.04.051
32. Huhn EA, Hoffmann I, De Tejada BM, et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020;20:128.
33. Bellos I, Pergialiotis V, Loutradis D, et al. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020;22(5):826-34.
34. Prajapati K, Nakum K. Prospective study to analyze calcium creatinine ratio in a spot sample of urine for early prediction of hypertensive disorders in pregnancy. Int J Med Biomed Stud. 2020;4(3):52-6.
35. Reis ZS, Pereira JB, Aparecida CA, et al. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: antenatal longitudinal feasibility study. J Obstet Gynaecol. 2020;40:1-6. DOI:10.1080/01443615.2020.1789851
36. Carbillon L. First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction. J Matern Fetal Neonatal Med. 2012;25(7):877-83.
37. Oancea M, Grigore M, Ciortea R, et al. Uterine Artery Doppler Ultrasonography for First Trimester Prediction of Preeclampsia in Individuals at Risk from Low-Resource Settings. Medicina. 2020;56:428. DOI:10.3390/medicina56090428
38. «Об утверждении Порядка оказания медицинской помощи по профилю "акушерство и гинекология"». Приказ Минздрава России №1130н от 20.10.2020 [Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi po profilyu ”akusherstvo i ginekologiya”. Prikaz Minzdrava Rossii №1130n ot 20.10.2020 (in Russian)].
39. Nagpal A, Nagpal D, Nagpalm L. Role of uterine artery doppler at 12 to 16 weeks of gestation for the prediction of preeclampsia in women: an observational study. Int J Clin Obstet Gynaecol. 2020;4(2):317-20.
40. Gassea C, Boutinb A, Cotéc M, et al. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study. Pregnancy Hypertens. 2018;12:178-82.
41. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
42. Nobles CJ, Mendola P, Mumford SL, et al. Preconception Blood Pressure and Its Change Into Early Pregnancy Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.14875
43. Ayala D, Hermida R, Mojon A, et al. Blood Pressure Variability During Gestation in Healthy and Complicated Pregnancies. Hypertension. 1997;30:611-8.
44. Baibing M, Xiaozhong W, Shanshan L, et al. Parameterization of the mid-trimester drop in blood pressure trajectory during pregnancy and its utility for predicting preeclampsia. J Hypertens. 2020;38:1355-66.
45. Godai K, Kabayama M, Gondo Y, et al. Day-to-day blood pressure variability is associated with lower cognitive performance among the Japanese community-dwelling oldest-old population: the SONIC study. Hypertens Res. 2020;43:404-11.
46. De Heus RA, Reumers SF, van der Have A. Day-to-Day Home Blood Pressure Variability is Associated with Cerebral Small Vessel Disease Burden in a Memory Clinic Population. J Alzheimer’s Dis. 2020;74(2):463-72.
47. Visaria A, Amorosa L. Measurement-to-measurement blood pressure variability as a predictor of cardiovascular disease outcomes. J Am Coll Cardiol. 2020;75(11):1947. DOI:10.1016/S0735-1097(20)32574-2
48. Webb A, Mazzucco S, Li L, et al. Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke. Stroke. 2018;49:62-7.
49. Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000;35(4):15-9.
50. Маянская С.Д., Ганеева А.В., Габидуллина Р.И. Вариабельность артериального давления у беременных с факторами риска преэклампсии. Казанский медицинский журнал. 2019;100(3):42633 [Mayanskaya SD, Ganeeva AV, Gabidullina RI. Variabel'nost' arterial'nogo davleniia u beremennykh s faktorami riska preeklampsii. Kazanskii medicinskii zhurnal. 2019;100(3):426-33 (in Russian)].
51. Ганеева А.В. Прогностическая значимость вариабельности артериального давления у беременных группы риска по развитию преэклампсии. Автореф. дис. … канд. мед. наук. Казань, 2019 [Ganeeva AV. Prognosticheskaia znachimost' variabel'nosti arterial'nogo davleniia u beremennykh gruppy riska po razvitiiu preeklampsii. Avtoref. dis. … kand. med. nauk. Kazan, 2019 (in Russian)].
52. Nuckols VR, Holwerda SW, Luehrs RE, et al. Beat-to-Beat Blood Pressure Variability in the First Trimester Is Associated With the Development of Preeclampsia in a Prospective Cohort Relation With Aortic Stiffness. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.15019
53. Ayala D, Hermida R, Mojon A, et al. Predictable Blood Pressure Variability in Healthy and Complicated Pregnancies. Hypertension. 2001;38:736-41.
54. Рунихина Н.К., Андросова Ю.М., Барт Б.Я. Динамика вариабельности сердечного ритма, артериального давления и состояния когнитивных функций при осложненном гипертензионным синдромом течении беременности. Медицинский вестник Северного Кавказа. 2011;3:47-51 [Runihina NK, Androsova YM, Bart BY. Dinamika variabel'nosti serdechnogo ritma, arterial'nogo davleniia i sostoyaniia kognitivnykh funktsii pri oslozhnennom gipertenzionnym sindromom techenii beremennosti. Medicinskii vestnik Severnogo Kavkaza. 2011;3:47-51 (in Russian)].
55. Antwi E, Amoakoh-Coleman M, Vieira DL, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS ONE. 2020;15(4):1-24.
56. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstet Gynecol Surv. 2018;73(1):40-55. DOI:10.1097/OGX.0000000000000522
57. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-15.
2. Hypertension in pregnancy: diagnosis and management. NICE guideline. 2019. Available at: www.nice.org.uk/guidance/ng133. Accessed: 20.10.2021.
3. American College of Obstetricians and Gynecologists. Committee opinion No. 638: first-trimester risk assessment for early-onset preeclampsia. Obstet Gynecol. 2015;126:25-7.
4. Adamyan LV, Artymuk NV, Bashmakova NV, et al. Gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode. Preeklampsiya. Eklampsiya. Klinicheskie rekomendatsii (protokol), utv. MZ RF 7 iyunya 2016 №15-4/10/2-3484. Moscow, 2016 (in Russian).
5. Boutin A, Gasse C, Demers S, et al. Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study. J Obstet Gynaecol Canada. 2017;40(5):572-8. DOI:10.1016/j.jogc.2017.07.025
6. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:237-60.
7. Sandström A, Snowden JM, Höijer J, et al. Clinical risk assessment in early pregnancy for preeclampsia in nulliparous women: A population based cohort study. PLoS ONE. 2019;14(11):1-16.
8. Wainstock T, Sergienko R, Sheiner JE. Who Is at Risk for Preeclampsia? Risk Factors for Developing Initial Preeclampsia in a Subsequent Pregnancy. J Clin Med. 2020;9:1103. DOI:10.3390/jcm9041103
9. Mosimann B, Amylidi-Mohr S, Surbek D, et al. First trimester screening for preeclampsia – a systematic review. Hypertens Pregnancy. 2019;39(1):1-11.
DOI:10.1080/10641955.2019.1682009
10. Amaral LM, Wallace K, Owens M, et al. Pathophysiology and Current Clinical Management of Preeclampsia. Curr Hypertens Rep. 2017;198:61.
11. Duan H, Zhao G, Xu B, et al. Maternal Serum PLGF, PAPPA, β-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia. Clin Lab. 2017;63(5):921-5.
12. Capriglione S, Plotti F, Terranova C, et al. Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. 2018;33(4):677-86. DOI:10.1080/14767058.2018.1495191
13. Goetzinger KR, Zhong Y, Cahill AG, et al. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013;32:1593-600.
14. Ratnik K, Rull K, Hanson E. Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. J Appl Lab Med. 2020;5(6):1156-71.
15. Karumanchi J, Roberts J, Taylor R. First-trimester placental growth factor, SFLT-1, and risk for preeclampsia. AJOG. 2003;189(6):14.
16. Robinson J, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007;197(2):174.e1-e5.
17. Maynard S, Simas T, Bur L. Soluble Endoglin for the Prediction of Preeclampsia in a High Risk Cohort. Hypertens Pregnancy. 2010;29(3):330-41.
18. Stepan H, Herraiz I, Schlembach D. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45(3):241-6.
19. Nikolaeva AE, Kajka IA, Yuabova EY, et al. Preeklampsiya. Vozmozhnosti prognozirovaniya. Akusherstvo i ginekologiya Sankt-Peterburga. 2017;1:8-12 (in Russian).
20. Luewan S, Teja M, Sirichotiyakul S, et al. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-9. DOI:10.11622/smedj.2017034
21. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 2008;115:1465-72.
22. Akolekar R, Syngelaki A, Beta J, et al. Maternal serum placental protein 13 at 11–13 weeks of gestation in pre-eclampsia. Prenat Diagn. 2009;29:1103-8.
23. Soongsatitanon A, Phupong V. Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med. 2020;16:1-6. DOI:10.1080/14767058.2020.1849127
24. Taylor BD, Ness RB, Olsen J, et al. Serum Leptin Measured in Early Pregnancy Is Higher in Women With Preeclampsia Compared With Normotensive Pregnant Women. Hypertension. 2015;65:594-9.
25. Akolekar R, Etchegaray A, Zhou Y, et al. Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25:320-7.
26. Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:753-60.
27. Nizyaeva NV, Kan NE, Tyutyunnik VL, et al. MikroRNK kak vazhnye diagnosticheckie predvestniki razvitiya akusherskoi patologii. Vestnik RAMN. 2015;70(4):484-92 (in Russian). DOI:10.15690/vramn.v70.i4.1416
28. Yin Y, Liu M, Yu H, et al. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;253:121-32.
29. Tarca AL, Romero R, Erez O, et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. J Matern Fetal Neonatal Med. 2020;33:1-12. DOI:10.1080/14767058.2019.1685964
30. Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci. 2019;20(12):2972. DOI:10.3390/ijms20122972
31. Bellos I, Pergialiotis V, Papapanagiotou A. Association between serum copeptin levels and preeclampsia risk: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;250:66-73. DOI:10.1016/j.ejogrb.2020.04.051
32. Huhn EA, Hoffmann I, De Tejada BM, et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020;20:128.
33. Bellos I, Pergialiotis V, Loutradis D, et al. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020;22(5):826-34.
34. Prajapati K, Nakum K. Prospective study to analyze calcium creatinine ratio in a spot sample of urine for early prediction of hypertensive disorders in pregnancy. Int J Med Biomed Stud. 2020;4(3):52-6.
35. Reis ZS, Pereira JB, Aparecida CA, et al. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: antenatal longitudinal feasibility study. J Obstet Gynaecol. 2020;40:1-6. DOI:10.1080/01443615.2020.1789851
36. Carbillon L. First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction. J Matern Fetal Neonatal Med. 2012;25(7):877-83.
37. Oancea M, Grigore M, Ciortea R, et al. Uterine Artery Doppler Ultrasonography for First Trimester Prediction of Preeclampsia in Individuals at Risk from Low-Resource Settings. Medicina. 2020;56:428. DOI:10.3390/medicina56090428
38. Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi po profilyu ”akusherstvo i ginekologiya”. Prikaz Minzdrava Rossii №1130n ot 20.10.2020 (in Russian).
39. Nagpal A, Nagpal D, Nagpalm L. Role of uterine artery doppler at 12 to 16 weeks of gestation for the prediction of preeclampsia in women: an observational study. Int J Clin Obstet Gynaecol. 2020;4(2):317-20.
40. Gassea C, Boutinb A, Cotéc M, et al. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study. Pregnancy Hypertens. 2018;12:178-82.
41. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
42. Nobles CJ, Mendola P, Mumford SL, et al. Preconception Blood Pressure and Its Change Into Early Pregnancy Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.14875
43. Ayala D, Hermida R, Mojon A, et al. Blood Pressure Variability During Gestation in Healthy and Complicated Pregnancies. Hypertension. 1997;30:611-8.
44. Baibing M, Xiaozhong W, Shanshan L, et al. Parameterization of the mid-trimester drop in blood pressure trajectory during pregnancy and its utility for predicting preeclampsia. J Hypertens. 2020;38:1355-66.
45. Godai K, Kabayama M, Gondo Y, et al. Day-to-day blood pressure variability is associated with lower cognitive performance among the Japanese community-dwelling oldest-old population: the SONIC study. Hypertens Res. 2020;43:404-11.
46. De Heus RA, Reumers SF, van der Have A. Day-to-Day Home Blood Pressure Variability is Associated with Cerebral Small Vessel Disease Burden in a Memory Clinic Population. J Alzheimer’s Dis. 2020;74(2):463-72.
47. Visaria A, Amorosa L. Measurement-to-measurement blood pressure variability as a predictor of cardiovascular disease outcomes. J Am Coll Cardiol. 2020;75(11):1947. DOI:10.1016/S0735-1097(20)32574-2
48. Webb A, Mazzucco S, Li L, et al. Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke. Stroke. 2018;49:62-7.
49. Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000;35(4):15-9.
50. Mayanskaya SD, Ganeeva AV, Gabidullina RI. Variabel'nost' arterial'nogo davleniia u beremennykh s faktorami riska preeklampsii. Kazanskii medicinskii zhurnal. 2019;100(3):426-33 (in Russian).
51. Ganeeva AV. Prognosticheskaia znachimost' variabel'nosti arterial'nogo davleniia u beremennykh gruppy riska po razvitiiu preeklampsii. Avtoref. dis. … kand. med. nauk. Kazan, 2019 (in Russian).
52. Nuckols VR, Holwerda SW, Luehrs RE, et al. Beat-to-Beat Blood Pressure Variability in the First Trimester Is Associated With the Development of Preeclampsia in a Prospective Cohort Relation With Aortic Stiffness. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.15019
53. Ayala D, Hermida R, Mojon A, et al. Predictable Blood Pressure Variability in Healthy and Complicated Pregnancies. Hypertension. 2001;38:736-41.
54. Runihina NK, Androsova YM, Bart BY. Dinamika variabel'nosti serdechnogo ritma, arterial'nogo davleniia i sostoyaniia kognitivnykh funktsii pri oslozhnennom gipertenzionnym sindromom techenii beremennosti. Medicinskii vestnik Severnogo Kavkaza. 2011;3:47-51 (in Russian).
55. Antwi E, Amoakoh-Coleman M, Vieira DL, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS ONE. 2020;15(4):1-24.
56. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstet Gynecol Surv. 2018;73(1):40-55. DOI:10.1097/OGX.0000000000000522
57. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-15.
2. Hypertension in pregnancy: diagnosis and management. NICE guideline. 2019. Available at: www.nice.org.uk/guidance/ng133. Accessed: 20.10.2021.
3. American College of Obstetricians and Gynecologists. Committee opinion No. 638: first-trimester risk assessment for early-onset preeclampsia. Obstet Gynecol. 2015;126:25-7.
4. Адамян Л.В., Артымук Н.В., Башмакова Н.В., и др. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол), утв. МЗ РФ 7 июня 2016 №15-4/10/2-3484. М., 2016 [Adamyan LV, Artymuk NV, Bashmakova NV, et al. Gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode. Preeklampsiya. Eklampsiya. Klinicheskie rekomendatsii (protokol), utv. MZ RF 7 iyunya 2016 №15-4/10/2-3484. Moscow, 2016 (in Russian)].
5. Boutin A, Gasse C, Demers S, et al. Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study. J Obstet Gynaecol Canada. 2017;40(5):572-8. DOI:10.1016/j.jogc.2017.07.025
6. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:237-60.
7. Sandström A, Snowden JM, Höijer J, et al. Clinical risk assessment in early pregnancy for preeclampsia in nulliparous women: A population based cohort study. PLoS ONE. 2019;14(11):1-16.
8. Wainstock T, Sergienko R, Sheiner JE. Who Is at Risk for Preeclampsia? Risk Factors for Developing Initial Preeclampsia in a Subsequent Pregnancy. J Clin Med. 2020;9:1103. DOI:10.3390/jcm9041103
9. Mosimann B, Amylidi-Mohr S, Surbek D, et al. First trimester screening for preeclampsia – a systematic review. Hypertens Pregnancy. 2019;39(1):1-11.
DOI:10.1080/10641955.2019.1682009
10. Amaral LM, Wallace K, Owens M, et al. Pathophysiology and Current Clinical Management of Preeclampsia. Curr Hypertens Rep. 2017;198:61.
11. Duan H, Zhao G, Xu B, et al. Maternal Serum PLGF, PAPPA, β-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia. Clin Lab. 2017;63(5):921-5.
12. Capriglione S, Plotti F, Terranova C, et al. Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. 2018;33(4):677-86. DOI:10.1080/14767058.2018.1495191
13. Goetzinger KR, Zhong Y, Cahill AG, et al. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013;32:1593-600.
14. Ratnik K, Rull K, Hanson E. Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. J Appl Lab Med. 2020;5(6):1156-71.
15. Karumanchi J, Roberts J, Taylor R. First-trimester placental growth factor, SFLT-1, and risk for preeclampsia. AJOG. 2003;189(6):14.
16. Robinson J, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007;197(2):174.e1-e5.
17. Maynard S, Simas T, Bur L. Soluble Endoglin for the Prediction of Preeclampsia in a High Risk Cohort. Hypertens Pregnancy. 2010;29(3):330-41.
18. Stepan H, Herraiz I, Schlembach D. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45(3):241-6.
19. Николаева А.Е., Кайка И.А., Юабова Е.Ю., и др. Преэклампсия. Возможности прогнозирования. Акушерство и гинекология Санкт-Петербурга. 2017;1:8-12 [Nikolaeva AE, Kajka IA, Yuabova EY, et al. Preeklampsiya. Vozmozhnosti prognozirovaniya. Akusherstvo i ginekologiya Sankt-Peterburga. 2017;1:8-12 (in Russian)].
20. Luewan S, Teja M, Sirichotiyakul S, et al. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-9. DOI:10.11622/smedj.2017034
21. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 2008;115:1465-72.
22. Akolekar R, Syngelaki A, Beta J, et al. Maternal serum placental protein 13 at 11–13 weeks of gestation in pre-eclampsia. Prenat Diagn. 2009;29:1103-8.
23. Soongsatitanon A, Phupong V. Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med. 2020;16:1-6. DOI:10.1080/14767058.2020.1849127
24. Taylor BD, Ness RB, Olsen J, et al. Serum Leptin Measured in Early Pregnancy Is Higher in Women With Preeclampsia Compared With Normotensive Pregnant Women. Hypertension. 2015;65:594-9.
25. Akolekar R, Etchegaray A, Zhou Y, et al. Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25:320-7.
26. Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:753-60.
27. Низяева Н.В., Кан Н.Е., Тютюнник В.Л., и др. МикроРНК как важные диагностичеcкие предвестники развития акушерской патологии. Вестник РАМН. 2015;70(4):484-92 [Nizyaeva NV, Kan NE, Tyutyunnik VL, et al. MikroRNK kak vazhnye diagnosticheckie predvestniki razvitiya akusherskoi patologii. Vestnik RAMN. 2015;70(4):484-92 (in Russian)]. DOI:10.15690/vramn.v70.i4.1416
28. Yin Y, Liu M, Yu H, et al. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;253:121-32.
29. Tarca AL, Romero R, Erez O, et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. J Matern Fetal Neonatal Med. 2020;33:1-12. DOI:10.1080/14767058.2019.1685964
30. Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci. 2019;20(12):2972. DOI:10.3390/ijms20122972
31. Bellos I, Pergialiotis V, Papapanagiotou A. Association between serum copeptin levels and preeclampsia risk: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;250:66-73. DOI:10.1016/j.ejogrb.2020.04.051
32. Huhn EA, Hoffmann I, De Tejada BM, et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020;20:128.
33. Bellos I, Pergialiotis V, Loutradis D, et al. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020;22(5):826-34.
34. Prajapati K, Nakum K. Prospective study to analyze calcium creatinine ratio in a spot sample of urine for early prediction of hypertensive disorders in pregnancy. Int J Med Biomed Stud. 2020;4(3):52-6.
35. Reis ZS, Pereira JB, Aparecida CA, et al. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: antenatal longitudinal feasibility study. J Obstet Gynaecol. 2020;40:1-6. DOI:10.1080/01443615.2020.1789851
36. Carbillon L. First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction. J Matern Fetal Neonatal Med. 2012;25(7):877-83.
37. Oancea M, Grigore M, Ciortea R, et al. Uterine Artery Doppler Ultrasonography for First Trimester Prediction of Preeclampsia in Individuals at Risk from Low-Resource Settings. Medicina. 2020;56:428. DOI:10.3390/medicina56090428
38. «Об утверждении Порядка оказания медицинской помощи по профилю "акушерство и гинекология"». Приказ Минздрава России №1130н от 20.10.2020 [Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi po profilyu ”akusherstvo i ginekologiya”. Prikaz Minzdrava Rossii №1130n ot 20.10.2020 (in Russian)].
39. Nagpal A, Nagpal D, Nagpalm L. Role of uterine artery doppler at 12 to 16 weeks of gestation for the prediction of preeclampsia in women: an observational study. Int J Clin Obstet Gynaecol. 2020;4(2):317-20.
40. Gassea C, Boutinb A, Cotéc M, et al. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study. Pregnancy Hypertens. 2018;12:178-82.
41. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
42. Nobles CJ, Mendola P, Mumford SL, et al. Preconception Blood Pressure and Its Change Into Early Pregnancy Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.14875
43. Ayala D, Hermida R, Mojon A, et al. Blood Pressure Variability During Gestation in Healthy and Complicated Pregnancies. Hypertension. 1997;30:611-8.
44. Baibing M, Xiaozhong W, Shanshan L, et al. Parameterization of the mid-trimester drop in blood pressure trajectory during pregnancy and its utility for predicting preeclampsia. J Hypertens. 2020;38:1355-66.
45. Godai K, Kabayama M, Gondo Y, et al. Day-to-day blood pressure variability is associated with lower cognitive performance among the Japanese community-dwelling oldest-old population: the SONIC study. Hypertens Res. 2020;43:404-11.
46. De Heus RA, Reumers SF, van der Have A. Day-to-Day Home Blood Pressure Variability is Associated with Cerebral Small Vessel Disease Burden in a Memory Clinic Population. J Alzheimer’s Dis. 2020;74(2):463-72.
47. Visaria A, Amorosa L. Measurement-to-measurement blood pressure variability as a predictor of cardiovascular disease outcomes. J Am Coll Cardiol. 2020;75(11):1947. DOI:10.1016/S0735-1097(20)32574-2
48. Webb A, Mazzucco S, Li L, et al. Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke. Stroke. 2018;49:62-7.
49. Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000;35(4):15-9.
50. Маянская С.Д., Ганеева А.В., Габидуллина Р.И. Вариабельность артериального давления у беременных с факторами риска преэклампсии. Казанский медицинский журнал. 2019;100(3):42633 [Mayanskaya SD, Ganeeva AV, Gabidullina RI. Variabel'nost' arterial'nogo davleniia u beremennykh s faktorami riska preeklampsii. Kazanskii medicinskii zhurnal. 2019;100(3):426-33 (in Russian)].
51. Ганеева А.В. Прогностическая значимость вариабельности артериального давления у беременных группы риска по развитию преэклампсии. Автореф. дис. … канд. мед. наук. Казань, 2019 [Ganeeva AV. Prognosticheskaia znachimost' variabel'nosti arterial'nogo davleniia u beremennykh gruppy riska po razvitiiu preeklampsii. Avtoref. dis. … kand. med. nauk. Kazan, 2019 (in Russian)].
52. Nuckols VR, Holwerda SW, Luehrs RE, et al. Beat-to-Beat Blood Pressure Variability in the First Trimester Is Associated With the Development of Preeclampsia in a Prospective Cohort Relation With Aortic Stiffness. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.15019
53. Ayala D, Hermida R, Mojon A, et al. Predictable Blood Pressure Variability in Healthy and Complicated Pregnancies. Hypertension. 2001;38:736-41.
54. Рунихина Н.К., Андросова Ю.М., Барт Б.Я. Динамика вариабельности сердечного ритма, артериального давления и состояния когнитивных функций при осложненном гипертензионным синдромом течении беременности. Медицинский вестник Северного Кавказа. 2011;3:47-51 [Runihina NK, Androsova YM, Bart BY. Dinamika variabel'nosti serdechnogo ritma, arterial'nogo davleniia i sostoyaniia kognitivnykh funktsii pri oslozhnennom gipertenzionnym sindromom techenii beremennosti. Medicinskii vestnik Severnogo Kavkaza. 2011;3:47-51 (in Russian)].
55. Antwi E, Amoakoh-Coleman M, Vieira DL, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS ONE. 2020;15(4):1-24.
56. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstet Gynecol Surv. 2018;73(1):40-55. DOI:10.1097/OGX.0000000000000522
57. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-15.
________________________________________________
2. Hypertension in pregnancy: diagnosis and management. NICE guideline. 2019. Available at: www.nice.org.uk/guidance/ng133. Accessed: 20.10.2021.
3. American College of Obstetricians and Gynecologists. Committee opinion No. 638: first-trimester risk assessment for early-onset preeclampsia. Obstet Gynecol. 2015;126:25-7.
4. Adamyan LV, Artymuk NV, Bashmakova NV, et al. Gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode. Preeklampsiya. Eklampsiya. Klinicheskie rekomendatsii (protokol), utv. MZ RF 7 iyunya 2016 №15-4/10/2-3484. Moscow, 2016 (in Russian).
5. Boutin A, Gasse C, Demers S, et al. Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study. J Obstet Gynaecol Canada. 2017;40(5):572-8. DOI:10.1016/j.jogc.2017.07.025
6. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:237-60.
7. Sandström A, Snowden JM, Höijer J, et al. Clinical risk assessment in early pregnancy for preeclampsia in nulliparous women: A population based cohort study. PLoS ONE. 2019;14(11):1-16.
8. Wainstock T, Sergienko R, Sheiner JE. Who Is at Risk for Preeclampsia? Risk Factors for Developing Initial Preeclampsia in a Subsequent Pregnancy. J Clin Med. 2020;9:1103. DOI:10.3390/jcm9041103
9. Mosimann B, Amylidi-Mohr S, Surbek D, et al. First trimester screening for preeclampsia – a systematic review. Hypertens Pregnancy. 2019;39(1):1-11.
DOI:10.1080/10641955.2019.1682009
10. Amaral LM, Wallace K, Owens M, et al. Pathophysiology and Current Clinical Management of Preeclampsia. Curr Hypertens Rep. 2017;198:61.
11. Duan H, Zhao G, Xu B, et al. Maternal Serum PLGF, PAPPA, β-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia. Clin Lab. 2017;63(5):921-5.
12. Capriglione S, Plotti F, Terranova C, et al. Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. 2018;33(4):677-86. DOI:10.1080/14767058.2018.1495191
13. Goetzinger KR, Zhong Y, Cahill AG, et al. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013;32:1593-600.
14. Ratnik K, Rull K, Hanson E. Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. J Appl Lab Med. 2020;5(6):1156-71.
15. Karumanchi J, Roberts J, Taylor R. First-trimester placental growth factor, SFLT-1, and risk for preeclampsia. AJOG. 2003;189(6):14.
16. Robinson J, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007;197(2):174.e1-e5.
17. Maynard S, Simas T, Bur L. Soluble Endoglin for the Prediction of Preeclampsia in a High Risk Cohort. Hypertens Pregnancy. 2010;29(3):330-41.
18. Stepan H, Herraiz I, Schlembach D. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45(3):241-6.
19. Nikolaeva AE, Kajka IA, Yuabova EY, et al. Preeklampsiya. Vozmozhnosti prognozirovaniya. Akusherstvo i ginekologiya Sankt-Peterburga. 2017;1:8-12 (in Russian).
20. Luewan S, Teja M, Sirichotiyakul S, et al. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-9. DOI:10.11622/smedj.2017034
21. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 2008;115:1465-72.
22. Akolekar R, Syngelaki A, Beta J, et al. Maternal serum placental protein 13 at 11–13 weeks of gestation in pre-eclampsia. Prenat Diagn. 2009;29:1103-8.
23. Soongsatitanon A, Phupong V. Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med. 2020;16:1-6. DOI:10.1080/14767058.2020.1849127
24. Taylor BD, Ness RB, Olsen J, et al. Serum Leptin Measured in Early Pregnancy Is Higher in Women With Preeclampsia Compared With Normotensive Pregnant Women. Hypertension. 2015;65:594-9.
25. Akolekar R, Etchegaray A, Zhou Y, et al. Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25:320-7.
26. Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:753-60.
27. Nizyaeva NV, Kan NE, Tyutyunnik VL, et al. MikroRNK kak vazhnye diagnosticheckie predvestniki razvitiya akusherskoi patologii. Vestnik RAMN. 2015;70(4):484-92 (in Russian). DOI:10.15690/vramn.v70.i4.1416
28. Yin Y, Liu M, Yu H, et al. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;253:121-32.
29. Tarca AL, Romero R, Erez O, et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. J Matern Fetal Neonatal Med. 2020;33:1-12. DOI:10.1080/14767058.2019.1685964
30. Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci. 2019;20(12):2972. DOI:10.3390/ijms20122972
31. Bellos I, Pergialiotis V, Papapanagiotou A. Association between serum copeptin levels and preeclampsia risk: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;250:66-73. DOI:10.1016/j.ejogrb.2020.04.051
32. Huhn EA, Hoffmann I, De Tejada BM, et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020;20:128.
33. Bellos I, Pergialiotis V, Loutradis D, et al. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020;22(5):826-34.
34. Prajapati K, Nakum K. Prospective study to analyze calcium creatinine ratio in a spot sample of urine for early prediction of hypertensive disorders in pregnancy. Int J Med Biomed Stud. 2020;4(3):52-6.
35. Reis ZS, Pereira JB, Aparecida CA, et al. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: antenatal longitudinal feasibility study. J Obstet Gynaecol. 2020;40:1-6. DOI:10.1080/01443615.2020.1789851
36. Carbillon L. First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction. J Matern Fetal Neonatal Med. 2012;25(7):877-83.
37. Oancea M, Grigore M, Ciortea R, et al. Uterine Artery Doppler Ultrasonography for First Trimester Prediction of Preeclampsia in Individuals at Risk from Low-Resource Settings. Medicina. 2020;56:428. DOI:10.3390/medicina56090428
38. Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi po profilyu ”akusherstvo i ginekologiya”. Prikaz Minzdrava Rossii №1130n ot 20.10.2020 (in Russian).
39. Nagpal A, Nagpal D, Nagpalm L. Role of uterine artery doppler at 12 to 16 weeks of gestation for the prediction of preeclampsia in women: an observational study. Int J Clin Obstet Gynaecol. 2020;4(2):317-20.
40. Gassea C, Boutinb A, Cotéc M, et al. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study. Pregnancy Hypertens. 2018;12:178-82.
41. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
42. Nobles CJ, Mendola P, Mumford SL, et al. Preconception Blood Pressure and Its Change Into Early Pregnancy Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.14875
43. Ayala D, Hermida R, Mojon A, et al. Blood Pressure Variability During Gestation in Healthy and Complicated Pregnancies. Hypertension. 1997;30:611-8.
44. Baibing M, Xiaozhong W, Shanshan L, et al. Parameterization of the mid-trimester drop in blood pressure trajectory during pregnancy and its utility for predicting preeclampsia. J Hypertens. 2020;38:1355-66.
45. Godai K, Kabayama M, Gondo Y, et al. Day-to-day blood pressure variability is associated with lower cognitive performance among the Japanese community-dwelling oldest-old population: the SONIC study. Hypertens Res. 2020;43:404-11.
46. De Heus RA, Reumers SF, van der Have A. Day-to-Day Home Blood Pressure Variability is Associated with Cerebral Small Vessel Disease Burden in a Memory Clinic Population. J Alzheimer’s Dis. 2020;74(2):463-72.
47. Visaria A, Amorosa L. Measurement-to-measurement blood pressure variability as a predictor of cardiovascular disease outcomes. J Am Coll Cardiol. 2020;75(11):1947. DOI:10.1016/S0735-1097(20)32574-2
48. Webb A, Mazzucco S, Li L, et al. Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke. Stroke. 2018;49:62-7.
49. Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000;35(4):15-9.
50. Mayanskaya SD, Ganeeva AV, Gabidullina RI. Variabel'nost' arterial'nogo davleniia u beremennykh s faktorami riska preeklampsii. Kazanskii medicinskii zhurnal. 2019;100(3):426-33 (in Russian).
51. Ganeeva AV. Prognosticheskaia znachimost' variabel'nosti arterial'nogo davleniia u beremennykh gruppy riska po razvitiiu preeklampsii. Avtoref. dis. … kand. med. nauk. Kazan, 2019 (in Russian).
52. Nuckols VR, Holwerda SW, Luehrs RE, et al. Beat-to-Beat Blood Pressure Variability in the First Trimester Is Associated With the Development of Preeclampsia in a Prospective Cohort Relation With Aortic Stiffness. Hypertension. 2020;76:1-8. DOI:10.1161/HYPERTENSIONAHA.120.15019
53. Ayala D, Hermida R, Mojon A, et al. Predictable Blood Pressure Variability in Healthy and Complicated Pregnancies. Hypertension. 2001;38:736-41.
54. Runihina NK, Androsova YM, Bart BY. Dinamika variabel'nosti serdechnogo ritma, arterial'nogo davleniia i sostoyaniia kognitivnykh funktsii pri oslozhnennom gipertenzionnym sindromom techenii beremennosti. Medicinskii vestnik Severnogo Kavkaza. 2011;3:47-51 (in Russian).
55. Antwi E, Amoakoh-Coleman M, Vieira DL, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS ONE. 2020;15(4):1-24.
56. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstet Gynecol Surv. 2018;73(1):40-55. DOI:10.1097/OGX.0000000000000522
57. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-15.
Авторы
Р.И. Габидуллина*1, А.В. Ганеева1, Т.Н. Шигабутдинова2
1 ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России, Казань, Россия;
2 ГАУЗ «Городская клиническая больница №7», Казань, Россия
*gabidullina@yandex.ru
1 Kazan State Medical University, Kazan, Russia;
2 City Clinical Hospital №7, Kazan, Russia
*gabidullina@yandex.ru
1 ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России, Казань, Россия;
2 ГАУЗ «Городская клиническая больница №7», Казань, Россия
*gabidullina@yandex.ru
________________________________________________
1 Kazan State Medical University, Kazan, Russia;
2 City Clinical Hospital №7, Kazan, Russia
*gabidullina@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.